PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Study To Evaluate The Safety And Efficacy Of ILV-094 In Subjects With Rheumatoid Arthritis
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2022-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 195
- Registration Number
- NCT00883896
- Locations
- πΊπΈ
Arizona Arthritis & Rheumatology Research, PLLC, Glendale, Arizona, United States
πΊπΈDesert Medical Advances, Palm Desert, California, United States
πΊπΈArthritis Center, Palm Harbor, Florida, United States
Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
- Conditions
- Hemophilia A
- Interventions
- Drug: moroctocog alfa (AF-CC) (ReFacto AF)Procedure: Laboratory tests
- First Posted Date
- 2009-04-20
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 208
- Registration Number
- NCT00884390
- Locations
- π¬π§
Pfizer Investigational Site, Manchester, United Kingdom
Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00880009
- Locations
- πΊπΈ
American Institute of Research, Whittier, California, United States
πΊπΈJoliet Oncology Hematology Associates, Joliet, Illinois, United States
πΊπΈOncology Specialists SC, Niles, Illinois, United States
An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2010-06-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT00879983
- Locations
- π¨π³
Pfizer Investigational Site, Shanghai, China
Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults
- Conditions
- Meningitis, Meningococcal
- Interventions
- Biological: rLP2086 vaccine or control
- First Posted Date
- 2009-04-13
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00879814
- Locations
- πΊπΈ
Miami Research Associates, Inc., South Miami, Florida, United States
Safety And PK Study Of CVX-060 In Patients With Advanced Solid Tumors
- Conditions
- MalignancyNeoplasmsAdvanced Solid TumorsCarcinomaCancer
- Interventions
- Biological: CVX-060
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 34
- Registration Number
- NCT00879684
- Locations
- πΊπΈ
Scottsdale Medical Imaging, Ltd., Scottsdale, Arizona, United States
πΊπΈPremiere Oncology of Arizona, Scottsdale, Arizona, United States
πΊπΈPremiere Oncology, A Medical Corporation, Santa Monica,, California, United States
Toviaz Post Marketing Surveillance Study
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2015-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3000
- Registration Number
- NCT00879398
- Locations
- π°π·
Hankook General Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
π°π·Shin Urology Clinic, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
π°π·Lee Urology Clinic, Namyangju-si, Gyeonggi-do, Korea, Republic of
A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorsNeoplasmsCarcinomaCancerMalignancy
- Interventions
- Biological: CVX-045
- First Posted Date
- 2009-04-10
- Last Posted Date
- 2010-12-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 40
- Registration Number
- NCT00879554
- Locations
- πΊπΈ
Pfizer Investigational Site, Philadelphia, Pennsylvania, United States
A Trial In Patients With Advanced Cancer And Leukemia
- First Posted Date
- 2009-04-08
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00878189
- Locations
- πΊπΈ
Anschutz Cancer Pavilion, Aurora, Colorado, United States
πΊπΈUniversity of Colorado Denver CTRC, Aurora, Colorado, United States
πΊπΈUniversity of Colorado Hospital, Aurora, Colorado, United States
Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration
- Conditions
- Age-Related MaculopathyEye DiseasesAge-Related MaculopathiesRetinal DegenerationMacular Degeneration
- Interventions
- Biological: RN6GBiological: Placebo
- First Posted Date
- 2009-04-07
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT00877032
- Locations
- πΊπΈ
Dedicated Phase 1, Phoenix, Arizona, United States
πΊπΈRetinal Consultants of AZ, Phoenix, Arizona, United States
πΊπΈInsight Diagnostic Imaging Center, Phoenix, Arizona, United States